A5066929627- Pharmacogenetics and Drug Metabolism
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Estrogen and related hormone effects
- Glutathione Transferases and Polymorphisms
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Chemical Reactions and Isotopes
- Drug Transport and Resistance Mechanisms
- RNA modifications and cancer
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Folate and B Vitamins Research
- Chemical Synthesis and Analysis
- Computational Drug Discovery Methods
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
- CRISPR and Genetic Engineering
Inserm
2009-2021
Université de Bordeaux
2010-2021
Institut Bergonié
2010-2021
Centre National de la Recherche Scientifique
2005-2021
Bordeaux Population Health
2009-2020
Université Toulouse III - Paul Sabatier
2018
Université Claude Bernard Lyon 1
2018
Institut Claudius Regaud
2018
Clinique Pasteur
2018
Centre de Recherche en Cancérologie de Toulouse
2018
Irinotecan is a major drug in the treatment of advanced colorectal cancer. Its active form SN38 metabolite, which cleared by biliary route after glucuronidation uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). UGT1A1 activity exhibits wide intersubject variability, part related to gene polymorphisms. The present review on impact deficient UGT1A1*28 variant irinotecan efficacy and toxicity was produced French joint workgroup comprising Group Clinical Onco-pharmacology...
Introduction: Glutathione S-transferase P1 (GSTP1) and excision-repair cross-complementing repair deficiency group 2 protein (ERCC2 or XPD) may modulate the activity of platinum derivatives. The SNPs, Ile105Val for GSTP1 Lys751Gln ERCC2, affect efficiency oxaliplatin in patients treated with an oxaliplatin-based regimen metastatic colorectal carcinoma. Patients & Methods: A total 107 first-line chemotherapy, 59 oxaliplatin–based 48 irinotecan-based regimen, were included retrospectively....
Non-Hodgkin B-cell lymphomas (B-NHL) mainly develop within lymph nodes as aggregates of tumor cells densely packed with their surrounding microenvironment, creating a niche specific to each lymphoma subtypes. In vitro preclinical models mimicking biomechanical forces, cellular and 3D organization remain scarce, while all these parameters are key determinants lymphomagenesis drug resistance. Using microfluidic method based on cell encapsulation inside permeable, elastic, hollow alginate...
Variations in clinical response to tamoxifen (TAM) may be related polymorphic cytochromes P450 (CYPs) involved forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (PopPK) model for and six metabolites determine clinically relevant factors of ENDO exposure. Concentration‐time data TAM 6 come from prospective, multicenter, 3‐year follow‐up study adjuvant (20 mg/day) patients with breast cancer, plasma samples drawn every months, genotypes 63 genetic...
A novel bimodal fluorescent/radiolabelled probe based on a pyridyltriazole scaffold (known as pyta) is reported here. The final dual imaging agent combines carboxylate functionalization, for biomolecule conjugation, with two distinct metal chelating sites: pyta-based tricarbonylrhenium moiety fluorescent and (99m)Tc(CO3)(+) core through the tridentate iminodiacetic acid (IDA) clamp SPECT reporter. heterodinuclear (99m)Tc/Re complex , well its non-radioactive dirhenium analog was prepared in...
GA101/obinutuzumab is a novel type II anti-CD20 monoclonal antibody (mAb), which more effective than rituximab (RTX) in preclinical and clinical studies when used combination with chemotherapy. Ca2+ signaling was shown to play role RTX-induced cell death. This report concerns the effect of GA101 on its involvement direct death induced by GA101. We reveal that triggered an intracellular increase mobilizing stores activating Orai1-dependent influx non-Hodgkin lymphoma lines primary B-Cell...
Abstract In humans, diets rich in fish oil (containing n‐3 FA) decrease the incidence of coronary artery diseases. This is thought to be caused by induction liver and skeletal muscle genes involved lipid oxidation, repression adipose tissue responsible for lipogenesis. FA are known reduce synthesis TG liver, resulting a plasma concentrations TG‐rich lipoproteins. On other hand, little possible effect on HDL metabolism. To investigate this question, female C57BI/6J mice were fed an...
Introduction: The National Cancer Institute (NCI)-60 panel consists of 60 human tumor cell lines initially established for screening thousands molecules antiproliferative activity. It has been powerful deciphering the relationships between anticancer drug cytotoxicity and molecular characteristics. We tested its potential interest establishing polymorphism genes involved in metabolism transport or DNA repair, extracted from NCI databases. Methods: Using polymerase chain reaction-restriction...
This study aimed to determine whether the BRCA1 haplotype was associated with trabectedin efficacy in soft-tissue sarcoma (STS) patients. We analysed single-nucleotide polymorphisms (SNPs) tumour specimens from 135 advanced STS patients enrolled published phase 2 trials or a compassionate-use programme of trabectedin. Forty-four treated doxorubicin and 85 localised served as controls. The 6-month nonprogression rate overall survival (OS) were according using log-rank tests. A favourable...
In addition to the effect of cytochrome P450 ( CYP ) 2D6 genetic polymorphisms, metabolism tamoxifen may be impacted by other factors with possible consequences on therapeutic outcome (efficacy and toxicity). This analysis focused pharmacokinetic (PK)‐pharmacogenetic evaluation in 730 patients adjuvant breast cancer included a prospective multicenter study. Plasma concentrations six major metabolites, genotype for 63 single‐nucleotide comedications were obtained 6 months after treatment...
Over 50% of colorectal cancer (CRC) patients develop metastases. The aim this study was to evaluate efficacy and tolerance first-line FOLFIRI® + bevacizumab (B) treatment for metastatic CRC, assess genetic polymorphisms as potential markers. Adult with histologically-proven, non-resectable CRC ECOG ≤ 2 were included. 14-day cycles consisted (5 mg/kg), irinotecan (180 mg/m2), bolus FU (400 mg/m2) leucovorin followed by 46-hour infusions (2400 mg/m2). Primary endpoint response rate according...
Cytochrome P450 1B1 (CYP1B1) is found in tumor tissue and suspected to play a role oncogenesis drug resistance. CYP1B1 gene polymorphisms have been associated with the risk of developing lung other cancers. They may be response anticancer drugs. We determined 4 frequent nonsynonymous human cell lines panels National Cancer Institute (NCI) Japanese Foundation for Research (JFCR): rs10012 (R48G), rs1056827 (A119S), rs1056836 (L432V), rs1800440 (N453S). Numerous drugs tested against these that...
Cytochrome P450 1B1 (CYP1B1) is mostly expressed in tumours and displays unusual properties. Its two polymorphic forms were differently associated with anticancer drug sensitivity. We decipher here the role of this polymorphism efficacy vitro, vivo clinical setting.From head-and-neck squamous cell carcinoma lines not expressing CYP1B1, we generated isogenic derivatives forms. Proliferation, invasiveness, stem characteristics, sensitivity to agents transcriptome analysed. Tumour growth...
Topoisomerase 1 (Top1), a nuclear enzyme involved in DNA relaxation, is the target of several anticancer drugs. TOP1 mutations occur camptothecin-resistant tumour cell lines. We explored, NCI panel 60 human lines, whether polymorphic variations gene could explain differences drug sensitivity. The 21 exons were fully studied as well five intronic domains that had previously been shown to harbour single nucleotide polymorphisms (SNPs) or mutations. PCR products covering whole exonic sequences...